12:00 AM
Nov 23, 2009
 |  BC Week In Review  |  Company News  |  Deals

Ligand, Merck deal

Ligand received a $2 million milestone payment from Merck's Organon N.V. subsidiary under a 2007 deal to discover, develop, and commercialize compounds for indications, including neuroscience and immunology. The...

Read the full 121 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >